By loading a chelation drug into a nano-sized homing device, researchers at Clemson University have reversed in an animal model the deadliest effects of chronic kidney disease, which kills more people in the United States each year than breast or prostate cancer.
When kidneys stop working properly, calcium builds up in artery tissue, leading to heart disease. Although nearly half a million Americans receive kidney dialysis, heart disease is the leading cause of death for people with chronic kidney disease.
“The findings are very exciting scientifically, but also for the thousands of patients who could potentially benefit from this technology one day,” said Naren Vyavahare, the Hunter Endowed Chair and professor of bioengineering at Clemson and the principal investigator of the research.
Chelation, a method of removing metals such as iron and lead from the body, has been used experimentally for some people with heart disease. The therapy is not approved by the Food and Drug Administration, but the National Institutes of Health has sponsored two large-scale, multi-center studies using ethylene diamine tetra-acetic acid, or EDTA, as chelation therapy for people with heart disease.
In clinical studies, EDTA is included in an infusion that circulates through the body; it’s systemic and non-specific. This method of chelation has shown good results in improving heart function, especially in diabetic patients, Vyavahare said. But EDTA infusion therapy is arduous (it requires 40 infusions over a period of a year), and it can cause side effects, including a depletion of calcium from the blood and from bone.
In 2014, Vyavahare’s team proved a targeted approach is effective. In animals without kidney disease, they loaded nanoparticles with EDTA and special antibodies that recognize and latch onto damaged elastin to deliver the therapy directly to arterial sites damaged by calcification.
Now, in a paper published Feb. 22, 2019, in Scientific Reports, a Nature publication, Vyavahare’s team describes how they developed an animal model that mimics a human’s chronic kidney disease. Animals were treated either with EDTA infusions, like in the NIH human trials, or with EDTA enclosed in a nanoparticle coupled with an antibody that seeks out damaged elastin. In animals that received the targeted therapy, calcium buildup was destroyed, without causing side effects, better than with EDTA infusions alone. Moreover, the calcification did not come back up to four weeks after the last injection, even though other signs of chronic kidney disease were present.
“Dr. Vyavahare’s work is extremely important for those of us who believe that calcium is not just a passive indicator of coronary disease, but also an active participant,” said Gervasio Lamas, chairman of medicine and chief of cardiology at Mount Sinai Medical Center in Miami Beach, Florida. Lamas, principal investigator of the NIH-funded Trial to Assess Chelation Therapy 2, was not involved in the Clemson study.
“The potential with a targeted drug is enormous, and the methodology for targeting that Dr. Vyavahare has developed is unique,” Lamas said.
Vyavahare and his co-authors wrote that in a previous study they showed that polyphenols, when delivered with nanoparticles, “regenerate degraded aortic elastin. Thus, there is an exciting opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and then restore medial elastin layers with (polyphenols).”
Vyavahare has been studying elastin degradation and damages caused by calcification for nearly 20 years. He’s director of the NIH-funded South Carolina Center of Biomaterials for Tissue Regeneration.
The nanoparticle delivery technology has been licensed by Elastrin Therapeutics, a startup company Vyavahare helped found. He serves as chief science officer of the company.
“With recent funding we received from NIH to carry out more studies on understanding how reversal of calcification works, and Elastrin Therapeutics Inc. licensing this technology from Clemson University, we believe we would be able to translate this approach for use in clinical trials within the next few years,” Vyavahare said.
Learn more: Cause of vascular disease in kidney failure reversed in animal model
The Latest on: Chronic kidney disease
[google_news title=”” keyword=”chronic kidney disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Chronic kidney disease
- Chronic Kidney Disease Warning Signs: What to Look Out Foron May 26, 2023 at 2:28 pm
OverviewA condition characterized by a gradual loss of kidney function. Early stages can be asymptomatic. Disease progression occurs slowly over a period of time.SymptomsSymptoms include poor appetite ...
- New research explores if pregnant mothers' exposure to toxic metals impacts babies' kidney developmenton May 26, 2023 at 12:23 pm
Chronic kidney disease is a growing problem worldwide and in the aging U.S. population. But could the groundwork for this progressive disease have been laid while its victims were still in utero?
- Chronic kidney disease symptoms and causeson May 26, 2023 at 9:08 am
A rep says Tina Turner died of natural causes, but over the years she battle several health issues including a stroke and kidney disease. Two months before her death, Turner said she regretted putting ...
- Do glucose-lowering medications have different effects on kidney outcomes?on May 26, 2023 at 5:04 am
Clinical trials involving patients with type 1 and 2 diabetes have shown that intensive glycemic control decreases the risk of albuminuria and kidney failure and prevents the estimated glomerular ...
- Tina Turner opened up about her kidney health 2 months before her deathon May 25, 2023 at 10:44 am
Two months prior to her death, Tina Turner opened up about putting herself "in great danger" by not taking action for her kidney health sooner.
- High blood pressure can lead to kidney disease and even kidney failure. Here's how to get it under control.on May 25, 2023 at 10:40 am
High blood pressure can damage the kidneys if left untreated, and is the second leading cause of kidney failure in the US.
- Kidney disease: How urine, blood tests may help predict progressionon May 24, 2023 at 11:20 pm
Researchers say biomarkers in blood and urine samples can be used to predict the progression of acute kidney injury to chronic kidney disease ...
- Hep C and Kidney Diseaseon May 23, 2023 at 9:28 am
Read on to learn more about the connection between hep C and chronic kidney disease and important topics you should consider discussing with a doctor if you have hep C. Hep C directly affects your ...
- Routine screening for kidney disease would be cost-effective, study argueson May 22, 2023 at 2:00 pm
With more effective treatments available, a study finds that screening all Americans for chronic kidney disease could keep hundreds of thousands from needing dialysis some day.
- Can chronic kidney disease be managed without dialysis?on May 20, 2023 at 5:00 pm
Chronic kidney disease (CKD) means your kidneys are damaged and can’t filter blood the way they should. The disease is called “chronic” because the damage to your kidneys happens slowly over ...
via Bing News